eli lilly's valuation is justified when you look at the growth profile, says ubs' bristow
Published 2 years ago • 3.1K plays • Length 3:43
Download video MP4
Download video MP3
Similar videos
-
7:14
eli lilly ceo david ricks on q3 results: the underlying growth story is fantastic
-
5:27
eli lilly's drop after earnings is a buying opportunity, says mizuho's jared holz
-
5:41
obesity drug could be a 'big upside' for eli lilly, says wells fargo's mohit bansal
-
5:22
eii lilly's weight-loss drug is 'much better' than others on the market, says wells fargo's bansal
-
32:23
super micro auditor resigns, eli lilly cuts outlook | bloomberg intelligence
-
6:42
the economic data this week were all surprising to the upside, says natwest's michelle girard
-
7:44
top analysts weigh in on apple and amazon's earnings
-
3:17
u.s. economy added just 12,000 jobs in october, impacted by hurricanes, boeing strike
-
3:07
jim cramer: eli lilly stock represents real value
-
2:00
eli lilly is one of our favorites in 2022: bank of america pharma analyst
-
26:41
ubs reports $1.4bn profit in q3
-
4:23
two bullish calls on eli lilly
-
3:48
three buys and a bail: abbvie, eli lilly, humana and moderna
-
3:35
the issue with eli lilly is the very competitive drug market, says short hills partners' weiss
-
3:51
eli lilly stock tumbles on q3 miss, zepbound sales fall short
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
3:49
wells fargo's mohit bansal sees durable growth behind eli lilly's blockbuster products
-
3:32
jim cramer on how lilly's alzheimer's drug compares to biogen's
-
2:14
eli lilly is in a great position to capture market share: investor
-
1:05
options action: traders bearish on eli lilly ahead of earnings
-
4:45
google has a 'big cost advantage' over microsoft azure, says d.a. davidson's gil luria
-
2:55
eli lilly's experimental obesity drug could be 'revolutionary,' says jim cramer
Clip.africa.com - Privacy-policy